Clinical Trial

Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The project aims to verify the therapeutic effect of neoadjuvant homoharringtonine combined with androgen deprivation therapy in patients with localized high-risk/very high-risk, regional lymph node-metastatic, or metastatic prostate cancer before radical prostatectomy through clinical trials, thereby identifying an effective treatment for patients with advanced prostate cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-04.
Status change: Not Yet Recruiting → Recruiting 2025-11-17
Trial Details
NCT Number NCT07163910
Lead Sponsor baotai Liang
Collaborators: The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Subei People's Hospital of Jiangsu Province, The First People Hospital of Nantong City
Conditions Prostate Cancer
Enrollment 93 participants
Start Date 2025-04-20
Primary Completion 2027-09-20 (estimated)
Study Completion 2027-12-20 (estimated)
Updated on ClinicalTrials.gov 2025-11-18